Results
H uman immunodeficiency virus 1 (HIV-1) infects mainly CD4 + T lymphocytes, monocytes and dendritic cells. After attachment to the CD4 receptor, viral envelope glycoproteins interact with a coreceptor protein (CXCR4 or CCR5) and trigger conformational changes that allow the fusion between the viral and cellular membranes 1 . HIV-1 replication requires uncoating, reverse transcription (RT) and viral DNA insertion into the cell genome. Uncoating may occur at the plasma membrane just after fusion, triggering RT, and then the pre-integration complex (PIC) would be actively transported into the nucleus 2, 3 . Alternatively, the viral core could be transported to the perinuclear region, with gradual uncoating and RT 2, 3 . A third model proposes that, after fusion, the viral capsid would remain intact, and RT would occur during transport, being completed at the nuclear pore before PIC transfer into the nucleus 2, 3 .
Numerous cellular molecules, including tetraspanins, regulate HIV-1 infection 4, 5 . Tetraspanins interact with other tetraspanins and with transmembrane receptors, lipids and intracellular proteins, organizing tetraspanin-enriched microdomains (TEMs) 6 . By means of TEMs, tetraspanins modulate the function of their associated partners, playing important roles in physiological and pathological processes [7] [8] [9] . In infected cells, HIV-1 assembly preferentially occurs at TEMs 10, 11 , although the role of tetraspanins as a budding co-factor is not yet well established 12 . Incorporation of tetraspanins into HIV-1 particles reduces virus-to-cell and viral-induced cell-cell fusion [13] [14] [15] . In target cells, CD63 controls CXCR4 surface expression, regulating viral entry 16 , and CD9 and CD81 inhibit HIV-1-induced membrane fusion 17 . Inhibition of membrane fusion by tetraspanins would prevent syncytia formation and support efficient viral cell-cell transfer 4 . Indeed, HIV-1 vpu protein downregulates CD81 in HIV-1 infected cells, promoting virion infectivity 18 . In contrast, CD63 is important for viral RT 19 .
SAMHD1 is a ubiquitous deoxyribonucleoside triphosphate triphosphohydrolase (dNTPase) that regulates intracellular dNTP levels 20 . SAMHD1 activity limits HIV-1 RT in resting monocytes, macrophages, dendritic cells and CD4 + T cells 21 . Low dNTP levels restrain viral DNA synthesis, blocking later stages of viral replication 22, 23 . In activated CD4 + T cells, SAMHD1 expression is reduced 24 , and the high levels of dNTPs contribute to viral infection 22 . SAMHD1 knockout mice also display increased RT and higher intracellular dNTP concentrations 25, 26 . The specific mechanisms regulating SAMHD1 enzymatic function remain undefined. In cycling cells, which display no HIV-1 restriction, SAMHD1 is phosphorylated at threonine 592 (T592) by cyclin-dependent kinases [27] [28] [29] . This phosphorylation is induced by interleukin-2 and − 7 in CD4 + T lymphocytes 30 . SAMHD1 also shows in vitro exonuclease activity against single-stranded DNAs and RNAs, displaying specificity for DNA-RNA duplexes which occur during RT 31 , and this activity is also involved in HIV-1 restriction 32, 33 . However, the control of phosphohydrolase and nuclease activities by T592 phosphorylation has been questioned 34, 35 , suggesting that additional regulatory mechanisms may be involved.
In this study, we show that SAMHD1 is a molecular partner of tetraspanin CD81, and that CD81 regulates RT by controlling SAMHD1 expression, thereby modulating the intracellular dNTP content.
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NATure MICrObIOlOgy spectrometry studies in primary human T lymphoblasts, not being validated at that time 36 . The association between CD81 and SAMHD1 was first probed by pull-down experiments using biotinylated tetraspanin C-terminal peptides. SAMHD1 specifically bound to CD81 C-terminal peptides, whereas no association was observed with tetraspanins CD9 and CD151 (Fig. 1a) . The association between endogenous molecules was then assessed by co-immunoprecipitation, and SAMHD1 was detected in CD81 immunoprecipitates and vice versa ( Fig. 1b) . These results indicate that SAMHD1 and CD81 directly associate through the CD81 C-terminal domain.
Since SAMHD1 is not expressed in T cell lines, like Jurkat or CEM ( Supplementary Fig. 1) , we have used primary T lymphoblasts and Hela cells to investigate its cellular distribution. Different permeabilizing conditions were used to co-stain CD81, which is a transmembrane protein expressed at the plasma membrane and in intracellular vesicular compartments, and SAMHD1, which has been mainly characterized as a nuclear protein, although also described at the cytoplasm of T lymphocytes 22 . Increasing concentrations of the permeabilizing agent allowed the detection of nuclear SAMHD1, but diminished the tetraspanin signal ( Supplementary  Fig. 2a-d ). Cytoplasmic localization of the enzyme could be observed with these permeabilizing conditions, as well as in Jurkat cells transfected with SAMHD1-GFP (green fluorescent protein) ( Supplementary Fig. 2a-e ). Using mild permeabilizing conditions (0.5% Triton X-100 for 5 min), intracellular CD81 was co-stained with cytoplasmic and nuclear SAMHD1 in primary T lymphoblasts and Hela-R5 cells ( Fig. 1c and Supplementary Fig. 2c ). However, the absence of clear co-localization in resting conditions indicates a transient interaction.
Therefore, we assessed SAMHD1 localization upon tetraspanin crosslinking in Hela-R5 cells stably expressing CD4 and CCR5. Cells plated onto poly-l-lysine (PLL), as a control, or onto anti-CD9 antibody showed weak SAMHD1 staining ( Fig. 1a ). Interestingly, the hydrolase accumulated in patches at the cellular basal layer b, Primary T lymphoblast lysates were immunoprecipitated and immunoblotted with SAMHD1 or CD81 antibodies. Control beads incubated with cell lysate and whole cell lysate (WCL) are shown. c, Hela-R5 cells or primary T lymphoblasts were plated onto PLL, fixed, permeabilized in PBS 0.5% Triton X-100 for 5 min, stained for CD81 (red) and SAMHD1 (green) and analysed by confocal microscopy. One single confocal plane is shown; nuclei are in blue. Scale bar, 10 μ m. d, Hela-R5 cells transfected with control siRNA (siControl) or CD81 siRNA (siCD81) were plated onto PLL (10 μ g ml -1 ), anti-CD9 (VJ1/20, 10 μ g ml -1 ), anti-CD4 (HP2/6, 10 μ g ml -1 ) or anti-CD81 (5A6, 10 μ g ml -1 ) monoclonal antibodies (mAbs) for 2 h, fixed, permeabilized in 0.5% Triton X-100 for 5 min and stained for SAMHD1 (polyclonal antibody). The images show a single confocal plane at a ventral position. Scale bars, 10 μ m. The graph shows the means ± s.e.m. of the number (counts per cell) of SAMHD1 + clusters (n = 50 cells, 3 independent experiments), analysed by one-way ANOVA with Tukey's post test. e, Duo-link immunoassay of primary T lymphoblasts plated onto PLL, permeabilized in PBS 0.5% Triton X-100 for 5 min and stained for SAMHD1 and CD81. SAMHD1/CD147 and CD81/ERM were used as negative and positive controls respectively. Scale bar, 10 μ m. The graph shows the number of dots per cell; each dot represents a single cell and the bars denote the mean of scatter plots; the data were analysed using one-way ANOVA with Dunn's post test.
Statistical significance values for Figs. 1-6 are provided in the Methods (see section 'Statistical analysis').
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upon CD81 or CD4 (a CD81 partner 7 ) crosslinking ( Fig. 1d ). This clustering was abrogated by siRNA depletion of CD81 (siCD81) ( Fig. 1d ). Moreover, in situ proximity ligation assays revealed SAMHD1-CD81 interactions in a significant number of primary T lymphoblasts ( Fig. 1e ). We used SAMHD1/CD147 as a negative control, since CD147 is a membrane receptor with higher expression than CD81, and CD81/ERM (ezrin, radixin and moesin) as a positive control, corroborating that proximity ligation signal could be attained between a membrane-bound molecule and an intracellular connector that were previously shown to interact at the uropod of T-lymphoblasts 37 .
CD81 positively regulates HIV-1 reverse transcription. Since SAMHD1 regulates HIV-1 RT, we assessed the role of CD81 in this step of the viral cycle. Hela-R5 cells were transfected with GFP, GFPtagged CD81 (CD81GFP) or a CD81 mutant lacking the C-terminal cytoplasmic region (CD81Δ cytGFP) 38 , and infected with wild-type R5-tropic HIV-1 (BaL strain). Early and late viral RT products were measured by quantitative polymerase chain reaction (qPCR) analysis. CD81GFP expression increased HIV-1 RT, and this effect was dependent on the CD81 C-terminal domain ( Fig. 2a , HIV-1 BaL). CD81GFP overexpression also highly increased RT of VSV-G-pseudotyped HIV-1 (HIV-VSV-G) ( Fig. 2a , HIV-VSV-G), which enters the cells via attachment of the VSV glycoprotein G, ruling out any effect of CD81 in HIV-1 entry, assembly or release 10, 17 . Moreover, CD81 positively regulated HIV-1 replication of single-cycle luciferase (Luc) reporter virus (pseudotyped with HIV-1 or VSV-G envelopes), through a process mediated by its C-terminal domain ( Fig. 2b) . Conversely, CD81 knockdown using siRNA ( Supplementary  Fig. 3a ), or full knockout using the CRISPR-Cas9 technology (CRISPR-Cas9-CD81; Fig. 2c ) in Hela-R5 cells reduced RT of both HIV-1 wild type and HIV-VSV-G ( Supplementary Fig. 3a-b ). CD81 deficiency also diminished the luciferase activity after infection with single-cycle HIV-1-R5-Luc or HIV-VSV-G-Luc reporter viruses (Fig. 2c ). The expression levels of CD4, CCR5 or tetraspanins CD82, CD9, CD151 or CD63 were not affected by CD81 knockdown or knockout ( Supplementary Fig. 3c-d ). In addition, pre-treatment of Hela-R5 cells with fluorescently labelled cytopermeable peptides corresponding to the sequence of the CD81 C-terminal region (CD81pept), which functionally mimics the effects of CD81 knockdown in different models 38, 39 , significantly reduced RT of wild-type HIV-1 and HIV-VSV-G ( Fig. 2d ), further corroborating the involvement of CD81 C-terminal domain in the regulation of viral RT.
In a more physiological setting, pre-treatment of primary T lymphoblasts with CD81pept clearly impaired RT of wild-type HIV-1 (NL4-3 strain) or HIV-VSV-G ( Fig. 3a) . Importantly, CD81 knockdown with siRNA in primary T lymphoblasts also specifically decreased RT (Fig. 3b ). Together, our results suggest that CD81 positively regulates HIV-1 RT of both R5-and X4-tropic viruses.
CD81 regulates intracellular dNTP levels via SAMHD1.
To determine whether the function of CD81 in RT relied on the regulation of SAMHD1, we analysed the effect of CD81 knockdown in Jurkat cells, which do not express SAMHD1 ( Supplementary Fig. 1 ). In these cells, CD81 knockdown or treatment with CD81pept did not alter the levels of RT products in comparison with control cells (Fig. 4a,b ), indicating that CD81 does not affect HIV-1 RT in the absence of SAMHD1.
SAMHD1 dNTPase activity was then directly analysed by quantification of the intracellular dNTP content in cell lysates after CD81 overexpression or depletion. In parallel to the effects observed on viral RT, the dNTP pool was significantly reduced in both Hela-R5 cells and primary T lymphoblasts depleted for CD81 ( Fig. 4c ) or treated with CD81pept ( Supplementary Fig. 3e ). Conversely, CD81GFP overexpression in Hela-R5 cells increased the dNTP content, which remained unaffected by CD81Δ cytGFP expression ( Fig. 4d ). These results indicate that CD81 regulates the intracellular dNTP content by associating with SAMHD1 through its C-terminal domain. CD81 controls SAMHD1 degradation by the proteasome and its subcellular localization. We next investigated the mechanism by which CD81 could regulate SAMHD1. Interestingly, CD81 deficiency increased the expression of SAMHD1, both in primary T lymphoblasts transfected with CD81 siRNA and in Hela-R5 CRISPR-Cas9-CD81 cells (Fig. 5a,b ). However, no differences were observed in the levels of SAMHD1 phosphorylation (Fig. 5a) . Although SAMHD1 has a predicted molecular weight of ∼ 70 kDa, additional bands with different molecular weights could be detected, suggesting cleavage, splicing variants 40 or post-translational modifications of the enzyme 27, 28, 41 . Specificity of the antibody was confirmed using whole cell lysates from cells expressing SAMHD1-GFP or transfected with SAMHD1 siRNA ( Supplementary Fig. 4 ). To assess whether the increase in SAMHD1 expression was related to altered protein degradation, cells were treated with MG132, which prevents proteasome function, or with ammonium chloride (NH 4 Cl), which blocks the acidification of lysosomes. SAMHD1 expression was twofold higher in Hela-R5 control cells upon treatment with MG132 ( Fig. 5c ), but it was only slightly affected by increasing concentrations of NH 4 Cl ( Fig. 5d ), indicating that the proteasome is the main route for SAMHD1 turnover. In CRISPR-Cas9-CD81 cells, despite the expected higher SAMHD1 basal levels in cells treated with the vehicle, the increase in the expression of the enzyme after MG132 treatment was completely abolished ( Fig. 5c ), suggesting that CD81 is essential for SAMHD1 degradation by the proteasome. Treatment of CRISPR-Cas9-CD81 cells with NH 4 Cl slightly increased SAMHD1 expression, suggesting that lysosomal degradation was unaffected or slightly favoured on proteasomal blockade by CD81 ( Fig. 5d ).
Since CD81 deletion increases SAMHD1 expression by protecting the enzyme from proteasomal degradation ( Fig. 5 ) and CD81 crosslinking triggers SAMHD1 accumulation beneath the plasma membrane ( Fig. 1d ), we investigated whether CD81 could regulate the subcellular distribution of SAMHD1. In the absence of CD81, SAMHD1 accumulated in cytoplasmic speckles, which displayed increased number and size with respect to control cells ( Fig. 6a and Supplementary Fig. 5a ,b). Similar results were obtained when cells were treated with CD81pept ( Fig. 6b and Supplementary Fig. 5a ,b). Accordingly, the presence and area of these SAMHD1 circular cytoplasmic structures was conversely reduced in CD81GFP-expressing cells, while no differences were observed between cells expressing CD81Δ cytGFP or GFP ( Fig. 6c and Supplementary Fig. 5c ).
To characterize these intracellular structures, Hela-R5 cells were co-stained with antibodies against SAMHD1 and markers of different intracellular compartments. We could not observe any co-localization between SAMHD1 cytoplasmic speckles and markers of late endosomes (HGS-HRS), multivesicular bodies (CD63) or lysosomes (LAMP-1) ( Fig. 6d and Supplementary Fig. 6 ). Interestingly, the circular intracellular structures that accumulated SAMHD1 partially co-localized with EEA1, a marker of early endosomes. SAMHD1-EEA1 co-localization was increased in CD81 knocked down cells, as quantified by Pearson's coefficient and the frequency of SAMHD1 co-localizing with EEA1 when compared with the total SAMHD1 signal ( Fig. 6d ).
Altogether, our results suggest that CD81 deletion controls SAMHD1 expression by protecting the enzyme from proteasomal degradation via its subcellular compartmentalization in early endosomes.
Discussion
In this study, we show that tetraspanin CD81 regulates HIV-1 RT through its molecular association with SAMHD1, and the control of the expression and subcellular localization of the hydrolase. We Articles NATure MICrObIOlOgy provide strong evidence of CD81 association with SAMHD1 in primary T lymphoblasts by (1) pull-down with synthetic peptides containing the CD81 C-terminal sequence but not of other tetraspanins;
(2) co-immunoprecipitation of endogenous CD81 and SAMHD1 using detergent lysis conditions (0.5% NP-40) that mostly disrupt TEMs, thus impairing indirect connections; and (3) in situ proximity ligation assay, which provides strong evidence that the CD81-SAMHD1 molecular association occurs in vivo. Moreover, crosslinking with monoclonal antibodies against CD81 and CD4 triggers SAMHD1 juxta-membrane clustering in a CD81-dependent manner. 
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SAMHD1 is a cellular inhibitor of HIV-1 RT in resting cells. Although widely studied in past years, the mechanisms that control this enzyme are not yet fully understood 21, 42 . SAMHD1 phosphorylation at T592 was shown to be important for the control of SAMHD1 RNase 33 and dNTPase 29, 43 activities. However, it was recently suggested that this phosphorylation cannot fully explain the restriction effect 35 . The SAMHD1 exonuclease activity is also controversial, with recent studies indicating that viral restriction is not related to this enzymatic activity 34, 44 , which could even derive from contaminants in the sample 45 . In the absence of CD81, SAMHD1 expression is induced and its dNTPase activity is increased, without noticeable differences in its phosphorylation levels.
Our results clearly indicate that CD81 is an important player in the regulation of SAMHD1-dependent restriction of HIV-1 replication, through a mechanism dependent on its C-terminal domain. When CD81 is depleted, SAMHD1 expression is increased and the subsequent reduction in the intracellular pool of dNTPs impairs viral RT and replication. The effects of CD81 depletion on RT are observed only 48 h post infection, probably because during the first 24 h, despite increased SAMHD1 activity, the remaining intracellular pool of dNTPs would be sufficient to allow initial viral replication until exhaustion observed at 48 h. Accordingly, HIV-1 reverse 
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transcriptase can efficiently synthesize viral DNA in the presence of low dNTP concentrations 46 . On the contrary, when CD81 is overexpressed, SAMHD1 expression is reduced and the cellular dNTP content is higher, allowing a huge increase in HIV-1 RT even at 24 h. The observed increase in dNTP levels in these cells was not as impressive as the increase in RT, further indicating that the viral reverse transcriptase is very sensitive to slight changes in the intracellular availability of dNTPs. Thus, even a small increase in the levels of these nucleotides is sufficient for the huge increase in viral genome replication.
The precise subcellular site where viral RT takes place remains to be determined 2, 3 . Although SAMHD1 has been mainly described as a nuclear protein, we and others 22 could detect this enzyme in the cytoplasm. In this regard, it has been recently shown that oxidized SAMHD1 is specifically located at the cytoplasm 41 . Tetraspanins, which are transmembrane proteins present in both the plasma membrane and intracellular compartments, can either promote or inhibit HIV-1 transmission, playing negative or positive roles in different steps of the viral cycle 4 . The involvement of tetraspanins in RT would imply that the virus highjacks intracellular membranes 
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to support its early replication. Interestingly, CD81 crosslinking triggers SAMHD1 enrichment beneath the plasma membrane, and CD81 knockdown increases SAMHD1 permanence in an early endosomal compartment, with partial SAMHD1 and EEA1 colocalization. Our results indicate that degradation of the hydrolase can partially occur through lysosomes but it is mostly dependent on the proteasome. CD81 does not affect SAMHD1 degradation by acidic compartments, but it clearly controls the degradation of the hydrolase by the proteasome. Therefore, CD81 regulation of SAMHD1 subcellular localization seems to be important for the turnover of the enzyme. Other cellular proteins have been described to regulate SAMHD1 degradation by the proteasome. Cyclin L2 interacts with SAMHD1 at the nucleus, driving its proteasomal degradation through a mechanism dependent on the ubiquitin ligase adaptor DCAF1 47 . Interaction with the eukaryotic elongation factor 1A1 (eEF1A1) at the cytoplasm also targets SAMHD1 for proteasomal turnover, through the association with Cullin4A and Rbx1 48 . Interestingly, we also detected eEF1A1 as a putative molecular partner of CD81 in our previous proteomic study 36 .
In summary, CD81 regulates HIV-1 early replication via direct association with SAMHD1, modulating the intracellular dNTP content through the control of SAMHD1 expression and subcellular localization. The evidence that SAMHD1 is included in TEMs highlights the importance of these membrane microdomains during HIV-1 replication, not only in the entry and assembly phases of the viral cycle, but also in RT. More detailed knowledge on how SAMHD1 blocks HIV-1 infection will provide insights to reinforce its restriction activity and prevent HIV-1 progression and AIDS. Moreover, the regulation of cellular dNTP levels by CD81 might be important in other physiological and pathological processes, like the autoimmune disorder Aicardi-Goutières syndrome or even in tumour progression.
Methods
Cells. The Hela P4 MAGI CCR5 + cells (Hela-R5) 17 were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: P4R5 MAGI from N. Landau, and were cultured in DMEM (Sigma) supplemented with 10% FCS (Invitrogen) and 1 µ g ml -1 puromycin (Sigma). Vβ 8 Jurkat T cell (J77 cl20), human T cell line CEM 1.3, and human kidney cell line HEK293T (ATCC) were cultured in RPMI 1640 or DMEM (Sigma) supplemented with 10% FCS. Cell lines from ATCC were authenticated by ATCC and were not further validated in our laboratory. Cells from the NIH were not validated further in our laboratory. Cell lines were routinely tested for mycoplasma contamination and were mycoplasma free. Peripheral blood lymphocytes were isolated from Buffy coats of healthy donors, and maintained as described 39 . Buffy coats were received from the Blood Transfusion Center of Comunidad de Madrid, and all donors signed their consent for the use of samples for research purposes. All the procedures using primary human cells were approved by the Ethics Committee of the Hospital Universitario de la Princesa.
Hela-R5 cells (8 × 10 6 ), human T lymphoblasts (2 × 10 7 ) or Jurkat cells (2 × 10 7 ) were washed twice with HBSS (Lonza), and transiently transfected by electroporation with siRNA (1 µ M) or plasmids (20 μ g) in OPTIMEM (Gibco, Invitrogen) at 240 V and 34 ms (Gene Pulser II, Bio-Rad). Overexpression, knockdown or gene deletion were confirmed by flow cytometry or western blotting.
Reagents and constructs. Tetramethylrhodamine (TAMRA) N-terminallabelled peptides with the sequences RRRRRRRCCGIRNSSVY (CD81) or RRRRRRRYSVNICRGCSS (Scrambled) were purchased from LifeTein. N-terminally biotinylated peptides containing a SGSG linker sequence connected to the cytoplasmic C-terminal domains of the proteins of interest were purchased from Ray Biotech, and have been previously described 36, 38 . The constructs CD81GFP and CD81Δ cytGFP were previously described 38 ; and SAMHD1-GFP was kindly provided by N. Landau (New York). Control siRNA and siRNA for CD81 CAATTTGTGTCCCTCGGGC (siCD81) were purchased from Eurogentec. We have validated three different sequences to knockdown CD81 obtaining similar phenotypes in other systems 38, 39 . siRNA for SAMHD1 was purchased from Dharmacon (SMARTpool ON-TARGETplus containing four different siRNA sequences).
Pull-down, immunoprecipitation and immunoblot assays. For immunoprecipitation, primary T lymphoblasts (2 × 10 7 ) were lysed in PBS 0.5% NP-40 containing protease and phosphastase inhibitors. Lysates were precleared for 2 h at 4 °C with protein G-Sepharose (Amersham Biosciences), and incubated for 2 h at 4 °C with anti-CD81 5A6 monoclonal (S. Levy, Stanford) or mouse polyclonal anti-SAMHD1 (Sigma) antibodies immobilized on protein G-Sepharose beads. After rinsing with lysis buffer, complexes were eluted in Laemmli buffer, and resolved by SDS-PAGE.
N-terminally biotinylated peptides (30 nmol) were conjugated to 40 μ l of streptavidin sepharose (GE Healthcare). Pull-down assays were carried out as previously described 38 . Briefly, cells were washed once with ice-cold PBS and lysed in PBS 1% NP-40 containing protease and phosphatase inhibitors (Complete, PhosSTOP; Roche). Lysates were precleared for 2 h at 4 °C with streptavidin sepharose (GE Healthcare) and incubated for 2 h at 4 °C with biotinylated peptides immobilized on streptavidin sepharose beads.
For immunoblotting, untreated cells or cells incubated with different concentrations of ammonium chloride (NH 4 Cl, Sigma) or MG132 (Sigma) for 6 h at 37 °C were lysed in PBS 1% Triton X-100 containing protease and phosphatase inhibitors. All blots were revealed with FUJIFILM LAS-4000 after membrane incubation with specific antibodies and peroxidase-conjugated secondary antibodies (Pierce). Primary antibodies were against: SAMHD1 (polyclonal antibody; Sigma), CD81 (5A6), α -tubulin (clone DM1A, Sigma), p150glued (BD Biosciences), cofilin (Abcam), and ERM (90.3; kindly provided by H. Furthmayr, Stanford). Band intensities were quantified using ImageGauge (FUJIFILM) and results normalized with respect to the intensity signal of the loading controls.
Flow cytometry. Cells were fixed in 2% paraformaldehyde (PFA; Electron Microscopy Sciences), permeabilized using the BD Cytofix/Cytoperm kit when observing intracellular proteins, and stained with primary antibodies followed by species-matching secondary antibodies (Invitrogen). Primary antibodies were anti-CCR5 (Santa Cruz), anti-SAMHD1 (polyclonal antibody; Sigma), anti-CD82 (TS82b, kindly provided by E. Rubinstein, Villejuif), and antibodies produced in our laboratory (anti-CD9 (VJ1/20), anti-CD151 (LIA1/1), anti-CD63 (Tea3/18) and anti-CD4 (HP2/6)) 17, 49, 50 . Data were acquired with a FACSCantoII flow cytometer (BD) and analysed with BD FACSDIVA (BD) or FlowJo (FlowJo LLC) software.
Fluorescence confocal microscopy. Cells were adhered onto PLL (Sigma), CD4, CD81 or CD9 monoclonal antibodies (10 μ g ml -1 ) for 2 h, or onto fibronectin (FN)-coated coverslips (20 μ g ml -1 , Sigma) for 2, 4 or 18 h at 37 °C, fixed in 4% PFA, permeabilized with PBS 0.1%, 0.5% or 1% Triton X-100 for 5 min or 30 min, stained with primary antibodies followed by species-matching secondary antibodies coupled to Alexa Fluor fluorochromes (Invitrogen) and mounted in Prolong antifading medium (Invitrogen). Primary antibodies were anti-CD81 (5A6), anti-SAMHD1 (monoclonal or polyclonal antibodies; Sigma), anti-EEA1, CD63 and LaminA (Santa Cruz), anti-HGS/HRS (Abcam) and Alexa-647-labelled anti-LAMP-1 (BioLegend). Duolink in situ proximity ligation assay (Sigma) was performed following the instructions provided with the kit. Primary antibodies were SAMHD1 (polyclonal antibody), CD81 (5A6), ERM (90.3) or CD147 (VJ1/9 17 ; produced in our laboratory).
Confocal images were obtained with a Zeiss LSM700 confocal scanning laser unit attached to an inverted epifluorescence microscope (Observer.Z1) fitted with a Pan APO Chromat 63× /1.4 oil immersion objective, using ZEN 2009 acquisition software (Carl Zeiss Microscopy GmbH). Images were analysed with ImageJ (NIH) software, using the Particle Analysis plugin. Measurement of Pearson's coefficient and the percentage of co-localized SAMHD1 and EEA1 was performed using Imaris (Bitplane), analysing three-dimensional stack confocal microscopy images. The SAMHD1 nuclear signal was excluded from the analysis.
HIV-1 viral preparation and infection.
Preparation of wild-type HIV-1 NL4-3 (X4-tropic) or BaL (R5-tropic), and VSV-G-pseudotyped HIV recombinant virus (HIV-VSV-G), which allows the analysis of replication independently of HIV entry, was performed as described 50 . Pseudotyped viruses with a luciferase reporter gene were produced by co-transfection of HEK293T cells with an equal mixture of the pNL4-3.LucR − E − reporter plasmid (N. Landau, NIH AIDS Reagent Program), and HIV-1 envelope expression plasmid (NIH AIDS Reagent Program) or pcDNA3-VSV plasmid (encoding the vesicular stomatitis virus G-protein) using calcium phosphate (Sigma). The pNL4-3.LucR − E − has frameshift mutations in Env (E -) and Vpr (R -), and a luciferase reporter gene inserted into the Nef gene. After 24 h of transfection, the medium was replaced, and 2 h later pseudotyped viruses were harvested, filtered (0.45 μ m), aliquoted and frozen at − 80 °C until further use. The viral titre was quantified using a Gag p24 ELISA kit (INNOTEST HIV-1 Antigen mAb; Innogenetic).
For analysis of HIV-1 RT, Hela-R5 cells were infected with 100 ng per 24 well of HIV-1 BaL or with 50 ng per 24 well of HIV-VSV-G, and primary T lymphoblasts or Jurkat cells were infected with 100 ng per 10 6 cells with HIV-1 NL4-3 or 200 ng per 10 6 cells with HIV-VSV-G. After 2 h of infection, cells were extensively washed and incubated at 37 °C for 24 or 48 h and lysed in 0.2% NP-40; total genomic DNA was extracted using a QiAmp DNA mini kit (Qiagen). qPCR analysis for the measurement of HIV reverse transcription was performed by amplifying genomic DNA using a Power SYBR Green PCR master mixture (Applied Biosystems): For quantification of number and size of fluorescent SAMHD1+ spots in Hela/R5 cells, or SAMHD1/EEA1 co-localization, two or three independent experiments were performed, and the number of cells analyzed in confocal microscopy images ranged from 20 to 400, depending on the experiment. In each independent experiment the number of cells analyzed for each condition was similar. Methods, page 17. Legends of Figure 1 For quantification of immunoblot signals, two or three independent experiments were performed. In each experiment, results were normalized with respect to the loading control. Methods, page 16; Legend of Figure 5 , page 26.
Data exclusions
Describe any data exclusions. no data were excluded from the analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
each experiment was performed two or three independent times, as stated in the Figure Legends , and data from all the experiments were pooled. All attempts of replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Not applicable. Our experimental groups were: 1-control cells compared with cells overexpressing CD81GFP or the mutant CD81dcytGFP; 2-or control cells compared with cells knocked-down for CD81 by siRNA or CD81 knock-out with the CRISPR/ Cas9 technology; 3-or control cells compared with cells treated with cellpermeable peptides with the sequence of the C-terminal region of CD81.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Measurement of cellular dNTP content was performed on blinded samples.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
All statistical analyses were performed with GraphPad Prism (GraphPad Software Inc For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All unique materials used are readily available from the authors, or from standard commercial sources, as indicated in the Methods section, page 20.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). Figure 4 ), in which it recognizes SAMHD1-GFP, and knock-down of SAMHD1 by siRNA.
